このページは自動翻訳されたものであり、翻訳の正確性は保証されていません。を参照してください。 英語版 ソーステキスト用。

Satiety Evaluation of Mature Okra Flour-incorporated Biscuit (MOFB)

2026年6月3日 更新者：Tan Chee Yee、Universiti Putra Malaysia

Evaluating the Impact of Mature Okra Flour-Incorporated Biscuits (MOFB) on Perceived Satiety Through the Satiety Labeled Intensity Magnitude (SLIM) Scale and Metabolomic Approach

This study aims to evaluate whether eating biscuits made with mature okra flour can help young adults feel fuller (enhance satiety) and change certain blood markers compared to eating standard biscuits.

Mature okra is a nutrient-dense agricultural by-product that is often discarded due to its tough texture. For this study, mature okra pods are dried and ground into a flour, which is then used to replace 10% of the wheat flour in a custom biscuit formulation.

Participants will take part in a single-blind, randomised trial where they will consume either the okra-incorporated biscuits or the standard control biscuits on separate occasions. Researchers will measure participants' perceived fullness over 165 minutes using a visual rating scale. Blood samples will also be collected at specific intervals during this time to evaluate blood glucose levels, appetite-related hormones, and metabolic responses.

調査の概要

状態

募集

条件

介入・治療

詳細な説明

Okra is one of the top ten most consumed vegetable crops by Malaysians, with 1.7kg per capita consumption as reported by the Department of Statistic Malaysia in 2023. Among the total 65.6 thousand tonnes of output available, around 7.7% of the okra is turned into waste and partially fed to the livestock. Mature okra becomes unmarketable and turns into waste because it develops a tougher, more fibrous texture and a less desirable taste, unlike tender, immature okra, which is typically preferred for consumption. Studies in the literature found that mature okra also possesses comparable nutrient content or is even better than immature okra in certain aspects. Incorporation of agricultural waste, for instance, mature okra, into food products can offer significant health advantages besides reducing waste and also promotes a sustainable future, aligning with the objectives of Sustainable Development Goals (SDGs) goal No.12. Besides, transforming mature okra and other agricultural by-products into functional or value-added foods is an urge to address environmental and unsustainable use of natural resources. This study aims to evaluate the impact of mature okra flour-incorporated biscuits (MOFB) on perceived satiety and metabolomic responses. Mature okra flour will be prepared by dehydrating and grinding okra pods, then incorporated into biscuits at 10% substitution of wheat flour. This ratio of mature okra flour incorporation is pre-determined based on the previous phase study, as this ratio of incorporation results in a better nutritional profile and an acceptable sensorial score. Subsequently, thirty healthy young adults will participate in a single-blind, randomised trial comparing MOFB and control biscuits. Satiety will be assessed using the SLIM scale and blood glucose measurements over 165 minutes post-consumption. Blood samples will be collected for hormone and metabolomic analyses using ELISA, RIA, and Liquid Chromatography-Mass Spectrometry (LC-MS). The findings will help determine whether MOFB enhances satiety and alters metabolic profiles, supporting its potential as a functional food for appetite regulation.

研究の種類

介入

入学 (推定)

30

段階

  • 適用できない

連絡先と場所

このセクションには、調査を実施する担当者の連絡先の詳細と、この調査が実施されている場所に関する情報が記載されています。

研究連絡先

研究連絡先のバックアップ

研究場所

  • マレーシア
    • Selangor
      • Serdang、Selangor、マレーシア、43400
        • 募集
        • Faculty of Medicine and Health Sciences, Universiti Putra Malaysia (UPM)
        • コンタクト：
        • 主任研究者：
          • Mohd Redzwan Sabran, PhD
        • 副調査官：
          • Chee Yee Tan

参加基準

研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。

適格基準

就学可能な年齢

  • 大人

健康ボランティアの受け入れ

はい

説明

Inclusion Criteria:

  • Young adults aged between 18 and 39 years.
  • Normal Body Mass Index (BMI).

Exclusion Criteria:

  • Smokers.
  • Pregnant or lactating women.
  • Individuals with daily medication prescriptions for chronic metabolic conditions, cardiovascular management, or hormonal regulation.

  • Use of daily medications/supplements that influence appetite regulation, metabolic signalling, or systemic metabolomic profiles, including:

    1. Hormonal contraceptives, glucocorticoids, and oral/injectable anti-obesity medications (e.g., GLP-1 agonists).
    2. Antihypertensives and lipid-lowering agents (statins).
    3. Chronic Nonsteroidal Anti-Inflammatory Drugs (NSAIDs).
    4. Daily fibre supplements.

研究計画

このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。

研究はどのように設計されていますか？

デザインの詳細

  • 主な目的：他の
  • 割り当て：ランダム化
  • 介入モデル：並列代入
  • マスキング：独身

武器と介入

参加者グループ / アーム
介入・治療
実験的：Mature Okra Flour-incorporated Biscuit (MOFB) Group
Young adult participants assigned to this group will consume the functional biscuit formulation incorporated with mature okra flour. Perceived satiety, metabolomic profiles, and appetite signalling will be assessed post-ingestion.
他の：Mature Okra Flour-incorporated Biscuit (MOFB)
Standard biscuit formulation manufactured where 10% of the wheat flour is substituted with mature okra flour, designed to enhance the nutritional profile while maintaining acceptable sensory scores.
アクティブコンパレータ：Control Biscuit Group
Young adult participants assigned to this group will consume the standard control biscuit formulation made with 100% wheat flour. Perceived satiety, metabolomic profiles, and appetite signalling will be assessed post-ingestion.
他の：Control Biscuit
Standard biscuit formulation manufactured using 100% wheat flour, designed to match the sensory profile and appearance of the experimental biscuit without the inclusion of mature okra flour.

この研究は何を測定していますか？

主要な結果の測定

結果測定
メジャーの説明
時間枠
Satiety Response
時間枠：Baseline (0 minutes) and post-consumption at 15, 45, 75, 105, 135, and 165 minutes
The satiety response after biscuit consumption will be determined by the Satiety Labeled Intensity Magnitude (SLIM) scale. The SLIM scale consists of a 100mm vertical line with labelled phrases to indicate satiety: "greatest imaginable fullness", "extremely full", "very full", "moderately full", "slightly full", "neither hungry nor full", "slightly hungry", "moderately hungry", "very hungry", and "extremely hungry", and "greatest imaginable hunger". The first satiety survey is filled before breakfast (time 0), and the remaining surveys at 15, 45, 75, 105, 135 and 165 min later.
Baseline (0 minutes) and post-consumption at 15, 45, 75, 105, 135, and 165 minutes
Change in Plasma Insulin Concentration
時間枠：Fasting state (0 minutes), 75 minutes, and 165 minutes post-consumption
Plasma concentration of insulin will be measured using an enzyme-linked immunosorbent assay (ELISA) kit. This metric evaluates metabolic responses to the biscuit interventions.
Fasting state (0 minutes), 75 minutes, and 165 minutes post-consumption
Change in Active Glucagon-Like Peptide-1 (GLP-1) Concentration
時間枠：Fasting state (0 minutes), 75 minutes, and 165 minutes post-consumption
Plasma concentration of active GLP-1 will be measured using an enzyme-linked immunosorbent assay (ELISA) kit. This metric evaluates anorexigenic hormone responses to the biscuit interventions.
Fasting state (0 minutes), 75 minutes, and 165 minutes post-consumption
Change in Plasma Peptide YY (PYY3-36) Concentration
時間枠：Fasting state (0 minutes), 75 minutes, and 165 minutes post-consumption
Plasma concentration of PYY3-36 will be measured using an enzyme-linked immunosorbent assay (ELISA) kit. This metric evaluates anorexigenic hormone responses to the biscuit interventions.
Fasting state (0 minutes), 75 minutes, and 165 minutes post-consumption
Change in Plasma Cholecystokinin (CCK) Concentration
時間枠：Fasting state (0 minutes), 75 minutes, and 165 minutes post-consumption
Plasma concentration of CCK will be determined using a radioimmunoassay (RIA) kit. This metric evaluates anorexigenic hormone responses to the biscuit interventions.
Fasting state (0 minutes), 75 minutes, and 165 minutes post-consumption
Change in Active Ghrelin Concentration
時間枠：Fasting state (0 minutes), 75 minutes, and 165 minutes post-consumption
Plasma concentration of active ghrelin will be measured using an enzyme-linked immunosorbent assay (ELISA) kit. This metric evaluates orexigenic hormone responses to the biscuit interventions.
Fasting state (0 minutes), 75 minutes, and 165 minutes post-consumption
Changes in Metabolite Profiles
時間枠：Fasting state (0 minutes) and 165 minutes post-consumption
For metabolomic analysis, the blood samples will be taken in the fasting state (0 min) and after the last satiety survey (165 min). Metabolites will be quantified by Liquid Chromatography-Mass Spectrometry (LC-MS) analysis, and the serum samples will be prepared according to In Vitro Diagnostics Research (IVDr) standard operating procedures.
Fasting state (0 minutes) and 165 minutes post-consumption

二次結果の測定

結果測定
メジャーの説明
時間枠
Blood Glucose Response
時間枠：Baseline (0 minutes) and post-consumption at 15, 45, 75, 105, 135, and 165 minutes
The capillary blood glucose will be measured using the finger-prick method during the fasting state (time 0), and at 15, 45, 75, 105, 135 and 165 min later.
Baseline (0 minutes) and post-consumption at 15, 45, 75, 105, 135, and 165 minutes
Ad Libitum Energy Intake at a Subsequent Meal
時間枠：At the end of the satiety evaluation session (165 minutes post-biscuit consumption)
Following the 165-minute satiety evaluation session, participants will be served an ad libitum meal consisting of fried rice and requested to consume as much as they want until comfortably full. The weight of the food consumed will be calculated by subtracting the remaining food weight from the initial served weight using a digital weighing scale (accurate to 1.0 g). Total energy intake will be calculated by multiplying the weight of the food consumed by the specific caloric content of the fried rice (expressed in kilocalories).
At the end of the satiety evaluation session (165 minutes post-biscuit consumption)

協力者と研究者

ここでは、この調査に関係する人々や組織を見つけることができます。

スポンサー

Universiti Putra Malaysia

捜査官

  • スタディチェア：Mohd Redzwan Sabran, PhD、Universiti Putra Malaysia

研究記録日

これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。

主要日程の研究

研究開始 (実際)

2026年5月15日

一次修了 (推定)

2026年6月25日

研究の完了 (推定)

2026年6月25日

試験登録日

最初に提出

2026年5月28日

QC基準を満たした最初の提出物

2026年6月3日

最初の投稿 (実際)

2026年6月8日

学習記録の更新

投稿された最後の更新 (実際)

2026年6月8日

QC基準を満たした最後の更新が送信されました

2026年6月3日

最終確認日

2026年6月1日

詳しくは

本研究に関する用語

キーワード

その他の研究ID番号

  • JKEUPM-2025-1085
  • GP-IPS/2024/9813100 (その他の助成金/資金番号：Universiti Putra Malaysia)

個々の参加者データ (IPD) の計画

個々の参加者データ (IPD) を共有する予定はありますか?

いいえ

IPD プランの説明

Individual participant data will not be publicly shared to protect participant confidentiality in accordance with institutional ethics committee guidelines. However, aggregated study data and final statistical outcomes will be made available upon reasonable request to the corresponding author.

医薬品およびデバイス情報、研究文書

米国FDA規制医薬品の研究

いいえ

米国FDA規制機器製品の研究

いいえ

この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。

類似の治験を検索

スポンサーと協力者

医学的状態

薬物療法

CROs by country

CROs in Cambodia

条件

まれな病気

薬物療法

ダイエットサプリメント

スポンサー/協力者

場所

購読する